Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Scilex Holding (SCLX) Current Deferred Revenue (2022 - 2025)

Scilex Holding has reported Current Deferred Revenue over the past 4 years, most recently at $407000.0 for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue fell 8.95% to $407000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $407000.0, a 8.95% decrease, with the full-year FY2025 number at $407000.0, down 8.95% from a year prior.
  • Current Deferred Revenue reached $407000.0 in Q4 2025 per SCLX's latest filing, down from $417000.0 in the prior quarter.
  • The five-year high for Current Deferred Revenue was $516000.0 in Q2 2023, with the low at $264000.0 in Q4 2022.
  • The 4-year median for Current Deferred Revenue is $447000.0 (2024), against an average of $439000.0.
  • Peak YoY movement for Current Deferred Revenue: soared 85.98% in 2023, then decreased 9.11% in 2024.
  • Tracing SCLX's Current Deferred Revenue over 4 years: stood at $264000.0 in 2022, then soared by 85.98% to $491000.0 in 2023, then decreased by 8.96% to $447000.0 in 2024, then fell by 8.95% to $407000.0 in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $407000.0, $417000.0, and $427000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.